Dear Sir, Submitting herewith the Disclosure 29(1) as required under SEBI (SAST) Regulations, 2011 submitted by Mr Padam Dugar the acquirer . Kindly take the same on records. For ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 4.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Colinz Laboratories Ltd received disclosure under SEBI SAST Regulations regarding off-market acquisition of equity shares on May 21, 2026. Mr. Padam Dugar acquired 3,16,000 shares (12.54%), while three Persons Acting in Concert (Annjana Dugar, Likhitta Dugar, and Antariksh Dugar) acquired additional shares totalling 62,000 (2.47%). The acquirer group collectively purchased 3,78,000 shares representing 15.01% of the company's total share capital of Rs. 2,51,91,000 (25,19,100 shares of Rs. 10 each). Prior to this acquisition, all acquirers held zero shares. The acquirer and PACs have explicitly stated they do not belong to the Promoter/Promoter group.
An outsider acquiring 15.01% stake in a single off-market transaction is a significant development. This represents creeping acquisition as the group crosses into substantial shareholding territory, bringing them closer to the 25% threshold that would trigger mandatory open offer requirements under SEBI regulations.